Applying scientific criteria to therapeutic interchange: A balanced analysis of low-molecular-weight heparins

Journal of Thrombosis and Thrombolysis

Volumn 11, Issue 3, 2001, Pages 247-259

  Merli, Geno J ^a   Vanscoy, Gordon J ^b   Rihn, Thomas L ^c   Groce, James B ^d   McCormick, William ^e  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c DUQUESNE UNIVERSITY   (United States)

^d Campbell University   (United States)

^e NONE   (United States)

Author keywords

Low molecular weight heparins; Scientific criteria; Therapeutic interchange

Indexed keywords

ACETYLSALICYLIC ACID; ARDEPARIN; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; TINZAPARIN;

BIOEQUIVALENCE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG LABELING; DRUG MARKETING; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HEART MUSCLE ISCHEMIA; HUMAN; MALPRACTICE; MEDICOLEGAL ASPECT; META ANALYSIS; NEGLIGENCE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; REVIEW; VEIN THROMBOSIS;

ANTICOAGULANTS; COST SAVINGS; DELIVERY OF HEALTH CARE; EVIDENCE-BASED MEDICINE; GUIDELINES; HEALTH POLICY; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; THERAPEUTIC EQUIVALENCY;

EID: 0035170385     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011969005756     Document Type: Review

References (60)

1. ASHP national survey of pharmacy practice in acute care settings: Prescribing and transcribing - 1998. American Society of Health-System Pharmacists
2. ASHP statement on the formulary system
3. Sixth ACCP Consensus Conference on Antithrombotic Therapy
4. Position Statement on the Guidelines for Therapeutic Interchange
5. Policy H-125.991 Drug Formularies and Therapeutic Interchange
6. Therapeutic substitution and formulary systems. American College of Physicians
7. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting
8. Role of low-molecular-weight heparins in the management of patients with unstable angina pectoris and non-Q-wave acute myocardial infarction
9. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group
10. Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease
11. Clinical and humanistic outcomes in patients with gastroesophageal reflux disease converted from omeprazole to lansoprazole
12. Cost analysis of therapeutic interchange of calcium channel blockers for the treatment of hypertension: Unexpected results from a conversion program
13. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: Examining some unanswered questions regarding location of treatment, product type, and dosing frequency
14. From the Food and Drug Administration
15. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
16. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)
17. Comparative effectiveness of low-molecular-weight heparins after therapeutic interchange
18. Pharmacokinetics of low molecular weight heparins in animal models
19. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina
20. Preclinical biochemistry and pharmacology of low molecular weight heparins in vivo-studies of venous and arterial thrombosis
21. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty: Evaluation during hospitalization and three months after discharge
22. Prevention of VTE after knee arthroplasty: A randomized double-blind trial comparing enoxaparin with warfarin
23. Enoxaparin in low molecular weight heparin and warfarin for the prevention of venous thromboembolic disease after elective knee replacement surgery
24. Prevention of deep vein thrombosis after hip replacement - Comparison between two low-molecular heparins, tinzaparin and enoxaparin
25. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group
26. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thrombosis after major trauma
27. Enoxaparin is superior to unfractionated heparin in the prevention of thromboembolic events in medical patients at increased thromboembolic risk
28. Comparison of the efficacy and safety of the low-molecular weight heparin enoxaparin with unfractionated heparin in the prevention of deep venous thrombosis in patients with acute ischemic stroke
29. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of VTE after elective neurosurgery
30. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: A double-blind, randomized comparison. The North American Fragmin Trial Investigators
31. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis
32. Comparison of once-daily subcutaneous fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis
33. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group
34. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire
35. Optimizing anticoagulant therapy in the management of pulmonary embolism
36. Outpatient treatment of pulmonary embolism with dalteparin
37. Prevention of venous thromboembolism
38. Heparin and low-molecular-weight heparin mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety
39. Subcutaneous enoxaparin once or twice daily compared to intravenous unfractionated heparin for treatment of venous thromboembolic disease
40. Frequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with once- or twice-daily low-molecular-weight heparin
41. Fragmin in unstable angina pectoris or in non-Q-wave acute myocardial infarction (the FRIC study). Fragmin in unstable coronary artery disease
42. Can we differentiate the low-molecular-weight heparins?
43. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial
44. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: One-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events
45. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: A double-blind, randomized comparison. North American Fragmin Trial Investigators
46. The post-discharge prophylactic management of the orthopedic patient with low-molecular-weight heparin: Enoxaparin
47. Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis
48. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective
49. Low molecular weight heparins in the outpatient management of venous thromboembolism
50. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis
51. Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?
52. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis
53. Therapeutic interchange of low-molecular-weight heparins
54. Prevention of venous thromboembolism
55. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group
56. Long term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomized multicentre study
57. Prevention of deep vein thrombosis after major knee surgery - A randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo